StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)
Investment analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April […]
More Stories
Market Review: Stocks Resume Gains on Improving Investor and Consumer Sentiment
By Panos Mourdoukoutas U.S. stocks resumed gains during the trading week that began May 27, driven by Nvidia’s strong earnings,...
Missing Montreal – 20 Years Without MLB Expos
By Donald Laible Charles Frederick “Boots” Day takes great pride in having played for the Montreal Expos. Retired from professional...
Ukraine Launches Drone Strikes on Air Bases Deep Inside Russia
By Jacob Burg Ukraine launched a massive drone strike on June 1, hitting multiple Russian airbases, according to the Russian...
Iran Says It Has Some Details of US Proposal for New Nuclear Deal
By Ryan Morgan Iranian Foreign Minister Abbas Araghchi has seen some of the first details of a U.S.-drafted proposal for...
Wexford Capital LP Buys New Shares in NVIDIA Co. (NASDAQ:NVDA)
Wexford Capital LP bought a new position in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) during the 4th quarter,...
Best Streaming Stocks To Keep An Eye On – May 30th
NVIDIA, AppLovin, Spotify Technology, Live Nation Entertainment, and Walt Disney are the five Streaming stocks to watch today, according to...